The Impact of Evolving Treatment Options in Multiple Myeloma, Part 6
A panel of experts in multiple myeloma review the use of quadruplet therapy in clinical practice and the impact on patients’ depth of response.
The Impact of Evolving Treatment Options in Multiple Myeloma, Part 5
Joseph Mikhael, MD, reviews the phase 2 GRIFFIN trial evaluating the use of quadruplet therapy, daratumumab plus VRd, in patients with multiple myeloma, and the panel comments on the use of quadruplet therapy.
The Impact of Evolving Treatment Options in Multiple Myeloma, Part 4
Multiple myeloma experts share insights on guiding treatment decisions to provide optimal care for patients.
The Impact of Evolving Treatment Options in Multiple Myeloma, Part 3
Joe Mikhael, MD, provides an overview of minimal residual disease and assesses the prognostic impact for a patient with multiple myeloma.
The Impact of Evolving Treatment Options in Multiple Myeloma, Part 2
Ryan Haumschild, PharmD, MS, MBA, comments on the use of triplet regimens as the standard of care treatment for patients with multiple myeloma, and Thomas Ollis, MS, RPh, shares a community practice perspective.
The Impact of Evolving Treatment Options in Multiple Myeloma, Part 1
Joseph Mikhael, MD, reviews the history of multiple myeloma treatment and comments on the evolution of care.
